TY - JOUR
T1 - Cost Effectiveness of Mailed Outreach Programs for Colorectal Cancer Screening
T2 - Analysis of a Pragmatic, Randomized Trial
AU - Kapinos, Kandice A.
AU - Halm, Ethan A.
AU - Murphy, Caitlin C.
AU - Santini, Noel O.
AU - Loewen, Adam C.
AU - Skinner, Celette Sugg
AU - Singal, Amit G.
N1 - Funding Information:
The authors thank the Parkland Health and Hospital System for partnership in our PROSPR research initiative. The authors also appreciate support from the Polymedco Corporation for providing FIT kits and reagents for the trial. Kandice A. Kapinos, Ph.D. (Formal analysis: Lead; Methodology: Lead; Writing – original draft: Lead; Writing – review & editing: Supporting), Ethan Halm (Conceptualization: Equal; Data curation: Equal; Funding acquisition: Equal; Writing – review & editing: Equal), Caitlin Murphy (Conceptualization: Equal; Formal analysis: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting), Noel Santini (Data curation: Equal; Writing – review & editing: Supporting), Adam C. Loewen (Data curation: Equal; Writing – review & editing: Supporting), Celette Sugg Skinner (Conceptualization: Equal; Funding acquisition: Equal; Writing – review & editing: Supporting), Amit Singal (Conceptualization: Equal; Data curation: Equal; Funding acquisition: Equal; Writing – review & editing: Equal) Funding This study was conducted as part of the National Cancer Institute-funded consortium Population-Based Research Optimizing Screening through Personalized Regiments (PROSPR) with support from National Institutes of Health/National Cancer Institute U54CA163308, UM1CA222035, UL1TR001105; U01 CA221940, and P30 CA142543, as well as Cancer Prevention and Research Institute of Texas PP160075. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Funding This study was conducted as part of the National Cancer Institute-funded consortium Population-Based Research Optimizing Screening through Personalized Regiments (PROSPR) with support from National Institutes of Health/National Cancer Institute U54CA163308, UM1CA222035, UL1TR001105; U01 CA221940, and P30 CA142543, as well as Cancer Prevention and Research Institute of Texas PP160075. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2022 AGA Institute
PY - 2022/10
Y1 - 2022/10
N2 - Background & Aims: Clinical guidelines for colorectal cancer (CRC) screening suggest use of either stool-based tests or colonoscopy – modalities that differ in recommended screening intervals, adherence, and costs. We know little about the long-term cost differences in population-health outreach strategies to promote these strategies. Methods: We conducted a cost-effectiveness analysis to compare 2 mailed outreach strategies to increase CRC screening from a pragmatic, randomized clinical trial: mailed fecal immunochemical test (FIT) kits vs invitations to complete a screening colonoscopy. We built a 10-year Markov chain Monte Carlo microsimulation model to account for differences in screening intervals, adherence, and costs. Results: Mailed FIT kits had a lower 10-year average per-person cost of screening relative to colonoscopy invitations ($1139 vs $1725) but with 10.89 fewer months of compliance and 60 fewer advanced neoplasia detected (37 advanced adenomas and 23 CRC). Incremental cost effectiveness ratios for colonoscopy invitations compared with mailed FIT kits were $55.23, $15.84, and $25.48 per additional covered month, advanced adenoma, and CRC, respectively. Although FIT was the preferred strategy at low willingness-to-pay thresholds, the 2 strategies were equal at a willingness-to-pay threshold of $41.31 per covered month gained. Conclusion: Mailed FIT or colonoscopy invitations are both options to improve CRC screening completion and advanced neoplasia detection, and the choice of outreach strategy may differ by a health system's willingness-to-pay threshold. Mailed FIT kits are less expensive than colonoscopy invitations but result in fewer months of screening compliance and advanced neoplasia detected.
AB - Background & Aims: Clinical guidelines for colorectal cancer (CRC) screening suggest use of either stool-based tests or colonoscopy – modalities that differ in recommended screening intervals, adherence, and costs. We know little about the long-term cost differences in population-health outreach strategies to promote these strategies. Methods: We conducted a cost-effectiveness analysis to compare 2 mailed outreach strategies to increase CRC screening from a pragmatic, randomized clinical trial: mailed fecal immunochemical test (FIT) kits vs invitations to complete a screening colonoscopy. We built a 10-year Markov chain Monte Carlo microsimulation model to account for differences in screening intervals, adherence, and costs. Results: Mailed FIT kits had a lower 10-year average per-person cost of screening relative to colonoscopy invitations ($1139 vs $1725) but with 10.89 fewer months of compliance and 60 fewer advanced neoplasia detected (37 advanced adenomas and 23 CRC). Incremental cost effectiveness ratios for colonoscopy invitations compared with mailed FIT kits were $55.23, $15.84, and $25.48 per additional covered month, advanced adenoma, and CRC, respectively. Although FIT was the preferred strategy at low willingness-to-pay thresholds, the 2 strategies were equal at a willingness-to-pay threshold of $41.31 per covered month gained. Conclusion: Mailed FIT or colonoscopy invitations are both options to improve CRC screening completion and advanced neoplasia detection, and the choice of outreach strategy may differ by a health system's willingness-to-pay threshold. Mailed FIT kits are less expensive than colonoscopy invitations but result in fewer months of screening compliance and advanced neoplasia detected.
KW - Colonoscopy
KW - Fecal Immunochemical Test
KW - Safety-net Health System
UR - http://www.scopus.com/inward/record.url?scp=85128177437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128177437&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2022.01.054
DO - 10.1016/j.cgh.2022.01.054
M3 - Article
C2 - 35144024
AN - SCOPUS:85128177437
SN - 1542-3565
VL - 20
SP - 2383-2392.e4
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 10
ER -